Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Analysis of neurotransmitter levels in addiction-related brain regions during synthetic cathinone self-administration in male Sprague-Dawley rats.

Marusich JA, Gay EA, Blough BE.

Psychopharmacology (Berl). 2018 Sep 6. doi: 10.1007/s00213-018-5011-8. [Epub ahead of print]

PMID:
30191259
2.

Molecular and Behavioral Pharmacological Characterization of Abused Synthetic Cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-Fluoro-CUMYL-PICA.

Gamage TF, Farquhar CE, Lefever TW, Marusich JA, Kevin RC, McGregor IS, Wiley JL, Thomas BF.

J Pharmacol Exp Ther. 2018 May;365(2):437-446. doi: 10.1124/jpet.117.246983. Epub 2018 Mar 16.

PMID:
29549157
3.

Finding order in chemical chaos - Continuing characterization of synthetic cannabinoid receptor agonists.

Marusich JA, Wiley JL, Lefever TW, Patel PR, Thomas BF.

Neuropharmacology. 2018 May 15;134(Pt A):73-81. doi: 10.1016/j.neuropharm.2017.10.041. Epub 2017 Nov 4.

PMID:
29113898
4.

Tobacco's minor alkaloids: Effects on place conditioning and nucleus accumbens dopamine release in adult and adolescent rats.

Marusich JA, Darna M, Wilson AG, Denehy ED, Ebben A, Deaciuc AG, Dwoskin LP, Bardo MT, Lefever TW, Wiley JL, Reissig CJ, Jackson KJ.

Eur J Pharmacol. 2017 Nov 5;814:196-206. doi: 10.1016/j.ejphar.2017.08.029. Epub 2017 Aug 26.

PMID:
28844873
5.

Vaping Synthetic Cannabinoids: A Novel Preclinical Model of E-Cigarette Use in Mice.

Lefever TW, Marusich JA, Thomas BF, Barrus DG, Peiper NC, Kevin RC, Wiley JL.

Subst Abuse. 2017 Apr 7;11:1178221817701739. doi: 10.1177/1178221817701739. eCollection 2017.

6.

Delivery of nicotine aerosol to mice via a modified electronic cigarette device.

Lefever TW, Lee YO, Kovach AL, Silinski MA, Marusich JA, Thomas BF, Wiley JL.

Drug Alcohol Depend. 2017 Mar 1;172:80-87. doi: 10.1016/j.drugalcdep.2016.12.004. Epub 2017 Jan 18.

7.

Comparison of the discriminative stimulus and response rate effects of Δ9-tetrahydrocannabinol and synthetic cannabinoids in female and male rats.

Wiley JL, Lefever TW, Marusich JA, Craft RM.

Drug Alcohol Depend. 2017 Mar 1;172:51-59. doi: 10.1016/j.drugalcdep.2016.11.035. Epub 2017 Jan 11.

8.

Thermolytic Degradation of Synthetic Cannabinoids: Chemical Exposures and Pharmacological Consequences.

Thomas BF, Lefever TW, Cortes RA, Grabenauer M, Kovach AL, Cox AO, Patel PR, Pollard GT, Marusich JA, Kevin RC, Gamage TF, Wiley JL.

J Pharmacol Exp Ther. 2017 Apr;361(1):162-171. doi: 10.1124/jpet.116.238717. Epub 2017 Jan 13. Erratum in: J Pharmacol Exp Ther. 2017 May;361(2):245.

9.

Combination Chemistry: Structure-Activity Relationships of Novel Psychoactive Cannabinoids.

Wiley JL, Marusich JA, Thomas BF.

Curr Top Behav Neurosci. 2017;32:231-248. doi: 10.1007/7854_2016_17. Review.

PMID:
27753007
10.

Evaluation of first generation synthetic cannabinoids on binding at non-cannabinoid receptors and in a battery of in vivo assays in mice.

Wiley JL, Lefever TW, Marusich JA, Grabenauer M, Moore KN, Huffman JW, Thomas BF.

Neuropharmacology. 2016 Nov;110(Pt A):143-153. doi: 10.1016/j.neuropharm.2016.07.016. Epub 2016 Jul 20.

11.

Just add water: cannabinoid discrimination in a water T-maze with FAAH(-/-) and FAAH(+/+) mice.

Wiley JL, Lefever TW, Pulley NS, Marusich JA, Cravatt BF, Lichtman AH.

Behav Pharmacol. 2016 Aug;27(5):479-84. doi: 10.1097/FBP.0000000000000228.

12.

Pharmacological effects of methamphetamine and alpha-PVP vapor and injection.

Marusich JA, Lefever TW, Blough BE, Thomas BF, Wiley JL.

Neurotoxicology. 2016 Jul;55:83-91. doi: 10.1016/j.neuro.2016.05.015. Epub 2016 May 26.

13.

The new psychoactive substances 5-(2-aminopropyl)indole (5-IT) and 6-(2-aminopropyl)indole (6-IT) interact with monoamine transporters in brain tissue.

Marusich JA, Antonazzo KR, Blough BE, Brandt SD, Kavanagh PV, Partilla JS, Baumann MH.

Neuropharmacology. 2016 Feb;101:68-75. doi: 10.1016/j.neuropharm.2015.09.004. Epub 2015 Sep 8.

14.

The impact of gonadal hormones on cannabinoid dependence.

Marusich JA, Craft RM, Lefever TW, Wiley JL.

Exp Clin Psychopharmacol. 2015 Aug;23(4):206-16. doi: 10.1037/pha0000027.

15.

AB-CHMINACA, AB-PINACA, and FUBIMINA: Affinity and Potency of Novel Synthetic Cannabinoids in Producing Δ9-Tetrahydrocannabinol-Like Effects in Mice.

Wiley JL, Marusich JA, Lefever TW, Antonazzo KR, Wallgren MT, Cortes RA, Patel PR, Grabenauer M, Moore KN, Thomas BF.

J Pharmacol Exp Ther. 2015 Sep;354(3):328-39. doi: 10.1124/jpet.115.225326. Epub 2015 Jun 23.

16.

Effects of α-pyrrolidinopentiophenone and 4-methyl-N-ethylcathinone, two synthetic cathinones commonly found in second-generation "bath salts," on intracranial self-stimulation thresholds in rats.

Watterson LR, Burrows BT, Hernandez RD, Moore KN, Grabenauer M, Marusich JA, Olive MF.

Int J Neuropsychopharmacol. 2014 Oct 31;18(1). pii: pyu014. doi: 10.1093/ijnp/pyu014.

17.

Baths salts, spice, and related designer drugs: the science behind the headlines.

Baumann MH, Solis E Jr, Watterson LR, Marusich JA, Fantegrossi WE, Wiley JL.

J Neurosci. 2014 Nov 12;34(46):15150-8. doi: 10.1523/JNEUROSCI.3223-14.2014. Review.

18.

Determination of behaviorally effective tobacco constituent doses in rats.

Wiley JL, Marusich JA, Thomas BF, Jackson KJ.

Nicotine Tob Res. 2015 Mar;17(3):368-71. doi: 10.1093/ntr/ntu194. Epub 2014 Sep 30.

19.

Cross-substitution of Δ9-tetrahydrocannabinol and JWH-018 in drug discrimination in rats.

Wiley JL, Lefever TW, Cortes RA, Marusich JA.

Pharmacol Biochem Behav. 2014 Sep;124:123-8. doi: 10.1016/j.pbb.2014.05.016. Epub 2014 Jun 2.

20.

Pharmacology of novel synthetic stimulants structurally related to the "bath salts" constituent 3,4-methylenedioxypyrovalerone (MDPV).

Marusich JA, Antonazzo KR, Wiley JL, Blough BE, Partilla JS, Baumann MH.

Neuropharmacology. 2014 Dec;87:206-13. doi: 10.1016/j.neuropharm.2014.02.016. Epub 2014 Mar 2.

21.

Evaluation of sex differences in cannabinoid dependence.

Marusich JA, Lefever TW, Antonazzo KR, Craft RM, Wiley JL.

Drug Alcohol Depend. 2014 Apr 1;137:20-8. doi: 10.1016/j.drugalcdep.2014.01.019. Epub 2014 Feb 12.

22.

Evaluation of WIN 55,212-2 self-administration in rats as a potential cannabinoid abuse liability model.

Lefever TW, Marusich JA, Antonazzo KR, Wiley JL.

Pharmacol Biochem Behav. 2014 Mar;118:30-5. doi: 10.1016/j.pbb.2014.01.002. Epub 2014 Jan 9.

23.

The Reinforcing and Rewarding Effects of Methylone, a Synthetic Cathinone Commonly Found in "Bath Salts"

Watterson LR, Hood L, Sewalia K, Tomek SE, Yahn S, Johnson CT, Wegner S, Blough BE, Marusich JA, Olive MF.

J Addict Res Ther. 2012 Dec 1;Suppl 9. pii: 002.

24.

Moving around the molecule: relationship between chemical structure and in vivo activity of synthetic cannabinoids.

Wiley JL, Marusich JA, Huffman JW.

Life Sci. 2014 Feb 27;97(1):55-63. doi: 10.1016/j.lfs.2013.09.011. Epub 2013 Sep 23. Review.

25.

Peripherally selective diphenyl purine antagonist of the CB1 receptor.

Fulp A, Bortoff K, Zhang Y, Snyder R, Fennell T, Marusich JA, Wiley JL, Seltzman H, Maitra R.

J Med Chem. 2013 Oct 24;56(20):8066-72. doi: 10.1021/jm401129n. Epub 2013 Sep 27.

26.

Prediction and Prevention of Prescription Drug Abuse: Role of Preclinical Assessment of Substance Abuse Liability.

Marusich JA, Lefever TW, Novak SP, Blough BE, Wiley JL.

Methods Rep RTI Press. 2013 Jul:1-14.

27.

Cannabinoids in disguise: Δ9-tetrahydrocannabinol-like effects of tetramethylcyclopropyl ketone indoles.

Wiley JL, Marusich JA, Lefever TW, Grabenauer M, Moore KN, Thomas BF.

Neuropharmacology. 2013 Dec;75:145-54. doi: 10.1016/j.neuropharm.2013.07.022. Epub 2013 Aug 2.

28.

Structural analogs of pyrazole and sulfonamide cannabinoids: effects on acute food intake in mice.

Wiley JL, Marusich JA, Zhang Y, Fulp A, Maitra R, Thomas BF, Mahadevan A.

Eur J Pharmacol. 2012 Nov 15;695(1-3):62-70. doi: 10.1016/j.ejphar.2012.08.019. Epub 2012 Sep 6.

29.

Effects of synthetic cathinones contained in "bath salts" on motor behavior and a functional observational battery in mice.

Marusich JA, Grant KR, Blough BE, Wiley JL.

Neurotoxicology. 2012 Oct;33(5):1305-13. doi: 10.1016/j.neuro.2012.08.003. Epub 2012 Aug 23.

30.

Environmental enrichment during development decreases intravenous self-administration of methylphenidate at low unit doses in rats.

Alvers KM, Marusich JA, Gipson CD, Beckmann JS, Bardo MT.

Behav Pharmacol. 2012 Oct;23(7):650-7. doi: 10.1097/FBP.0b013e3283584765.

31.

Potent rewarding and reinforcing effects of the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV).

Watterson LR, Kufahl PR, Nemirovsky NE, Sewalia K, Grabenauer M, Thomas BF, Marusich JA, Wegner S, Olive MF.

Addict Biol. 2014 Mar;19(2):165-74. doi: 10.1111/j.1369-1600.2012.00474.x. Epub 2012 Jul 11.

32.

Sex differences in cannabinoid pharmacology: a reflection of differences in the endocannabinoid system?

Craft RM, Marusich JA, Wiley JL.

Life Sci. 2013 Mar 19;92(8-9):476-81. doi: 10.1016/j.lfs.2012.06.009. Epub 2012 Jun 20. Review.

33.

The kappa opioid receptor antagonist JDTic attenuates alcohol seeking and withdrawal anxiety.

Schank JR, Goldstein AL, Rowe KE, King CE, Marusich JA, Wiley JL, Carroll FI, Thorsell A, Heilig M.

Addict Biol. 2012 May;17(3):634-47. doi: 10.1111/j.1369-1600.2012.00455.x.

34.

Rimonabant abolishes sensitivity to workload changes in a progressive ratio procedure.

Marusich JA, Wiley JL.

Pharmacol Biochem Behav. 2012 Jun;101(4):575-80. doi: 10.1016/j.pbb.2012.03.004. Epub 2012 Mar 9.

35.

Escalation of cocaine intake with extended access in rats: dysregulated addiction or regulated acquisition?

Beckmann JS, Gipson CD, Marusich JA, Bardo MT.

Psychopharmacology (Berl). 2012 Jul;222(2):257-67. doi: 10.1007/s00213-012-2641-0. Epub 2012 Jan 17.

36.

1-Pentyl-3-phenylacetylindoles and JWH-018 share in vivo cannabinoid profiles in mice.

Wiley JL, Marusich JA, Martin BR, Huffman JW.

Drug Alcohol Depend. 2012 Jun 1;123(1-3):148-53. doi: 10.1016/j.drugalcdep.2011.11.001. Epub 2011 Nov 27.

37.

Hijacking of Basic Research: The Case of Synthetic Cannabinoids.

Wiley JL, Marusich JA, Huffman JW, Balster RL, Thomas BF.

Methods Rep RTI Press. 2011 Nov;2011. pii: 17971.

38.

Strain differences in self-administration of methylphenidate and sucrose pellets in a rat model of attention-deficit hyperactivity disorder.

Marusich JA, McCuddy WT, Beckmann JS, Gipson CD, Bardo MT.

Behav Pharmacol. 2011 Dec;22(8):794-804. doi: 10.1097/FBP.0b013e32834d623e.

39.

A translational behavioral model of mood-based impulsivity: Implications for substance abuse.

Gipson CD, Beckmann JS, Adams ZW, Marusich JA, Nesland TO, Yates JR, Kelly TH, Bardo MT.

Drug Alcohol Depend. 2012 Apr 1;122(1-2):93-9. doi: 10.1016/j.drugalcdep.2011.09.014. Epub 2011 Oct 5.

40.

Cue effects on methylphenidate self-administration in rats.

Marusich JA, Beckmann JS, Gipson CD, Bardo MT.

Behav Pharmacol. 2011 Oct;22(7):714-7. doi: 10.1097/FBP.0b013e32834afed1.

41.

High impulsivity in rats predicts amphetamine conditioned place preference.

Yates JR, Marusich JA, Gipson CD, Beckmann JS, Bardo MT.

Pharmacol Biochem Behav. 2012 Jan;100(3):370-6. doi: 10.1016/j.pbb.2011.07.012. Epub 2011 Jul 23.

42.

Social facilitation of d-amphetamine self-administration in rats.

Gipson CD, Yates JR, Beckmann JS, Marusich JA, Zentall TR, Bardo MT.

Exp Clin Psychopharmacol. 2011 Dec;19(6):409-19. doi: 10.1037/a0024682. Epub 2011 Jul 18.

43.

A multivariate assessment of individual differences in sensation seeking and impulsivity as predictors of amphetamine self-administration and prefrontal dopamine function in rats.

Marusich JA, Darna M, Charnigo RJ, Dwoskin LP, Bardo MT.

Exp Clin Psychopharmacol. 2011 Aug;19(4):275-84. doi: 10.1037/a0023897.

44.

Effect of environmental enrichment on escalation of cocaine self-administration in rats.

Gipson CD, Beckmann JS, El-Maraghi S, Marusich JA, Bardo MT.

Psychopharmacology (Berl). 2011 Mar;214(2):557-66. doi: 10.1007/s00213-010-2060-z. Epub 2010 Nov 6.

45.

Novelty seeking, incentive salience and acquisition of cocaine self-administration in the rat.

Beckmann JS, Marusich JA, Gipson CD, Bardo MT.

Behav Brain Res. 2011 Jan 1;216(1):159-65. doi: 10.1016/j.bbr.2010.07.022. Epub 2010 Jul 23.

46.

Methylphenidate as a reinforcer for rats: contingent delivery and intake escalation.

Marusich JA, Beckmann JS, Gipson CD, Bardo MT.

Exp Clin Psychopharmacol. 2010 Jun;18(3):257-66. doi: 10.1037/a0019814.

47.

Differences in impulsivity on a delay-discounting task predict self-administration of a low unit dose of methylphenidate in rats.

Marusich JA, Bardo MT.

Behav Pharmacol. 2009 Sep;20(5-6):447-54. doi: 10.1097/FBP.0b013e328330ad6d.

48.

Environmental and pharmacological factors in the development of noncontingent tolerance to cocaine in pigeons.

Marusich JA, Branch MN.

Exp Clin Psychopharmacol. 2009 Aug;17(4):266-82. doi: 10.1037/a0016682.

49.

Limitations to the generality of cocaine locomotor sensitization.

Marusich JA, Branch MN, Dallery J.

Exp Clin Psychopharmacol. 2008 Aug;16(4):282-92. doi: 10.1037/a0012874.

50.

Differences in the behavioral time course of effects of rate-increasing and rate-decreasing doses of cocaine in pigeons.

Marusich JA, Branch MN.

Pharmacol Biochem Behav. 2008 Apr;89(2):150-9. doi: 10.1016/j.pbb.2007.12.004. Epub 2007 Dec 8.

Supplemental Content

Loading ...
Support Center